



ZIOPHARM Oncology, Inc.
 Investor Relations Department
 One First Ave., Parris Building, # 34
 Navy Yard Plaza
 Boston, MA 02199
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	6.57
Trade Time:	4:00 PM ET May 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	4.45 - 7.99
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 17, 2017
[ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting](#)
- May 12, 2017
[ZIOPHARM Oncology Announces Pricing of \\$50 Million Follow-On Offering of Common Stock](#)
- May 2, 2017
[ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia](#)
- May 1, 2017
[ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities](#)
- Apr 24, 2017
[ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET](#)

Financials [\[View all \]](#)

- Feb 16, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 1, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016
[Quarterly Report \(10-Q\)](#)